Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director | June 11, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-06-11 | Direct | 228,104 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 40,565 · Balance 228,104 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Nancy E. Armitage Revocable Living Trust | 0 |
Reported balance
After 2019-01-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-01-22 · Other · Disposed 1,500 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2: The reporting person is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purposes, except to the extent of his pecuniary interest therein. |
| Director Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.22 · Expires 2023-06-03 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.77 · Expires 2025-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.27 · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: The reporting person is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purposes, except to the extent of his pecuniary interest therein.
F3: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F4: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F5: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F6: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 01:30 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001370087-26-000005 · ownership.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,104 Underlying: Common Stock · 40,565 shares Expires 2036-06-11 Read SEC document |
| June 26, 2025 Filed Jun 28, 2025 00:45 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001641172-25-017005 · ownership.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,539 Underlying: Common Stock · 40,565 shares Expires 2035-06-26 Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:08 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 29,700 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001628280-24-030638 · wk-form4_1719864523.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,974 Underlying: Common Stock · 29,700 shares Expires 2034-06-27 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:06 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 27,700 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-23-022738 · wk-form4_1687295199.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,274 Underlying: Common Stock · 27,700 shares Expires 2033-06-15 Read SEC document |
| September 16, 2022 Filed Oct 11, 2022 20:22 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 13,000 | $1.56 | $20,233.20 |
DisclosureSEC source: 0001628280-22-026245 · wf-form4_166551974738442.xml · nonDerivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 13,000 F1 · ownership.nature: Shirley A. Young is the Trustee of the Shirley A. Young Revocable Trust DTD 2/10/2004. Shirley A. Young is the wife of James Armitage. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 23:38 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 26,800 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005788 · wf-form4_164695546998763.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,574 Underlying: Common Stock · 26,800 shares Expires 2032-03-09 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:11 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001628280-21-012170 · wf-form4_162370144457487.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,774 Underlying: Common Stock · 22,000 shares Expires 2031-06-10 Read SEC document |
| March 19, 2021 Filed May 27, 2021 21:14 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 4,000 | $10.82 | $43,271.20 |
DisclosureSEC source: 0001628280-21-011230 · wf-form4_162215000508271.xml · nonDerivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,490 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.795 to $10.82, inclusive. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:17 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 28,858 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-20-075242 · a4.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,774 Underlying: Common Stock · 28,858 shares Expires 2030-06-17 Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:15 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 10,490 | $1.43 | $15,000.70 |
DisclosureSEC source: 0001104659-20-063174 · a4.xml · nonDerivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490 Read SEC document |
| April 16, 2020 Filed May 1, 2020 20:17 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 11,916 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001104659-20-055491 · a4.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,916 Underlying: Common Stock · 11,916 shares Expires 2030-04-16 F1 · derivative.exercise_date: 3,972 of the Stock Options vest on each of 4/16/2021, 2022 and 2023 Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:55 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 7,209 | Not disclosed Strike: $46.89 | Not disclosed |
DisclosureSEC source: 0001123292-19-000162 · edgar.xml · derivative · entry 7 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F5 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:55 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $149.22 | Not disclosed |
DisclosureSEC source: 0001123292-19-000162 · edgar.xml · derivative · entry 6 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F5 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:55 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $47.27 | Not disclosed |
DisclosureSEC source: 0001123292-19-000162 · edgar.xml · derivative · entry 5 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-01 F5 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:55 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $60.77 | Not disclosed |
DisclosureSEC source: 0001123292-19-000162 · edgar.xml · derivative · entry 4 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-01 F5 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:55 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $46.22 | Not disclosed |
DisclosureSEC source: 0001123292-19-000162 · edgar.xml · derivative · entry 3 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-06-03 F5 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F6 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:55 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Restricted Stock Units · Derivative | 4,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000162 · edgar.xml · derivative · entry 2 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,052 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F4 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F4 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F4 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:55 UTC | TESARO, Inc. TSRO · Entity 160894 | OtherCommon Stock | 1,500 | $75.00 | $112,500.00 |
DisclosureSEC source: 0001123292-19-000162 · edgar.xml · nonDerivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Nancy E. Armitage Revocable Living Trust Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). F2 · ownership.nature: The reporting person is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purposes, except to the extent of his pecuniary interest therein. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:06 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Restricted Stock Units · Derivative | 4,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-038342 · a4.xml · derivative · entry 2 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052 Underlying: Common Stock · 4,052 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of TESARO common stock. F3 · derivative.exercise_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. F3 · derivative.expiration_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:06 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Nonqualified Stock Option (right to buy) · Derivative | 7,209 | $0.00 Strike: $46.89 | $0.00 |
DisclosureSEC source: 0001104659-18-038342 · a4.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F1 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:28 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionDirector Nonqualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.36 | $0.00 |
DisclosureSEC source: 0001104659-17-058110 · a4.xml · derivative · entry 5 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The original grant of options to purchase 10,000 shares of common stock vested on May 14, 2015. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:28 UTC | TESARO, Inc. TSRO · Entity 160894 | SaleCommon Stock | 5,743 | $117.58 | $675,261.94 |
DisclosureSEC source: 0001104659-17-058110 · a4.xml · nonDerivative · entry 3 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported is a weighted average. The shares were sold in multiple transactions at prices ranging from $117.05 to $118.01, inclusive. The reporting person undertakes to provide to TESARO, Inc., any security holder of TESARO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:28 UTC | TESARO, Inc. TSRO · Entity 160894 | SaleCommon Stock | 4,257 | $116.52 | $496,025.64 |
DisclosureSEC source: 0001104659-17-058110 · a4.xml · nonDerivative · entry 2 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,743 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average. The shares were sold in multiple transactions at prices ranging from $116.03 to $117.00, inclusive. The reporting person undertakes to provide to TESARO, Inc., any security holder of TESARO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:28 UTC | TESARO, Inc. TSRO · Entity 160894 | Exercise / conversionCommon Stock | 10,000 | $26.36 | $263,600.00 |
DisclosureSEC source: 0001104659-17-058110 · a4.xml · nonDerivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 18:13 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $149.22 | $0.00 |
DisclosureSEC source: 0001104659-17-037534 · a4.xml · derivative · entry 1 Armitage James O · CIK 0001370087 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.